IP Library Granted Patent US 7,842,291
Granted Patent B1
US 7,842,291 · App. 11/802,321 · Granted Nov 30, 2010

Methods and compositions for diagnosing and treating diseases

Assignee: Celera Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,842,291
App. No.
11/802,321
Granted
Nov 30, 2010
Kind
B1
Abstract

Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.

Claims (4)

1. A method of inhibiting proliferation of pancreatic cancer cells, the method comprising contacting the pancreatic cancer cells with an isolated antibody that selectively binds to a SLC5A6 protein to thereby inhibit proliferation of the pancreatic cancer cells, wherein the amino acid sequence of the SLC5A6 protein comprises a sequence selected from the group consisting of SEQ ID NOS:7-9.

2. The method of claim 1 , wherein the antibody is coupled to at least one agent selected from the group consisting of drugs, toxins, differentiation inducers, and radionuclides.

3. The method of claim 1 , wherein the contacting step comprises administering a therapeutically effective amount of the isolated antibody to an individual harboring the pancreatic cancer cells.

4. The method of claim 2 , wherein the contacting step comprises administering a therapeutically effective amount of the isolated antibody to an individual harboring the pancreatic cancer cells.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2008
From: APPLERA CORPORATION
To: CELERA CORPORATION
Reel/Frame 021561/0124 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2007
From: VAN ORDEN, KAREN; HE, TAO; LEE, CANDY; RUBEN, STEVE; MOORE, PAUL A.; BIRSE, CHARLES E.; MESRI, MEHDI; JOSELOFF, ELIZABETH G.
To: APPLERA CORPORATION
Reel/Frame 019684/0770 →
Continuity (12)
Provisional Application 6083541900 · Aug 4, 2006
Provisional Application 6083347100 · Jul 27, 2006
Provisional Application 6083347000 · Jul 27, 2006
Provisional Application 6081961100 · Jul 11, 2006
Provisional Application 6081961200 · Jul 11, 2006
Provisional Application 6081961600 · Jul 11, 2006
Provisional Application 6081017900 · Jun 2, 2006
Provisional Application 6081018000 · Jun 2, 2006
Provisional Application 6081018300 · Jun 2, 2006
Provisional Application 6080215100 · May 22, 2006
Provisional Application 6080215300 · May 22, 2006
Provisional Application 6080215200 · May 22, 2006